Home › Research › Brain scans and imaging
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
Isadora Lopes Alves, Lyduine E Collij, Daniele Altomare, Giovanni B Frisoni, Laure Saint-Aubert, Pierre Payoux, Miia Kivipelto, Frank Jessen et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2020-04-12
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Primary include several amyloid PET measurements (Centiloid, SUVr, BPND , R1 ), and secondary are their changes from baseline, relationship to other amyloid markers (cerebrospinal fluid and visual assessment), and predictive value of AD-related decline. EXPECTED IMPACT: Determining the role of amyloid PET for the understanding of this complex disease and potentially improving secondary prevention trials.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Alves, I. L., Collij, L. E., Altomare, D., Frisoni, G. B., Saint-Aubert, L., Payoux, P., et al. (2020). Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.12069
Vancouver
Alves IL, Collij LE, Altomare D, Frisoni GB, Saint-Aubert L, Payoux P, et al. Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2020. doi:10.1002/alz.12069. PMID: 32281303.
BibTeX
@article{alves2020-32281303,
author = {Alves, Isadora Lopes and Collij, Lyduine E and Altomare, Daniele and Frisoni, Giovanni B and Saint-Aubert, Laure and Payoux, Pierre and Kivipelto, Miia and Jessen, Frank and others},
title = {{Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2020},
doi = {10.1002/alz.12069},
pmid = {32281303},
url = {https://doi.org/10.1002/alz.12069}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Primary include several amyloid PET measurements (Centiloid, SUVr, BPND , R1 ), and secondary are their changes from baseline, relationship to other amyloid markers (cerebrospinal fluid and visual assessment), and predictive value of AD-related decline.
- EXPECTED IMPACT: Determining the role of amyloid PET for the understanding of this complex disease and potentially improving secondary prevention trials.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Study designcohort study
- Participants2,000
- Evidence strengthModerate
How this study scored 69/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and free to read, so those were left out: it earned 41 of the 59 points we could judge it on, which is 69 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,000 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32281303) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 41 / 59 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 41 of the 59 points we could judge it on is 69 out of 100. |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Brain scans and imaging from nearby years
Also tagged “18f”
318 studies in the library carry the topic tag “18f”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 318 tagged studies.